153322-05-5
153322-05-5 結(jié)構(gòu)式
基本信息
中文別名
拉尼西明 英文別名
LaniceMine(1S)-1-phenyl-2-pyridin-2-ylethanamine
2-PyridineethanaMine, a-phenyl-, (aS)-
2-Pyridineethanamine, α-phenyl-, (αS)-
(S)-1-phenyl-2-(pyridin-2-yl)ethanamine
(1S)-1-PHENYL-2-(PYRIDIN-2-YL)ETHAN-1-AMINE
物理化學(xué)性質(zhì)
沸點(diǎn)307.7±27.0 °C(Predicted)
密度1.097±0.06 g/cm3(Predicted)
儲存條件-20°C儲存
溶解度≤20mg/ml in ethanol;30mg/ml in DMSO;5mg/ml in dimethyl formamide
酸度系數(shù)(pKa)8.29±0.10(Predicted)
形態(tài)neat oil
顏色Colorless to light yellow
常見問題列表
生物活性
Lanicemine (AZD6765) 是一種低捕獲的 NMDA 受體拮抗劑，Ki 為 0.56-2.1?μM。CHO 和爪蟾卵母細(xì)胞中，IC50 分別為 4-7 μM 和 6.4 μM。具有抗抑郁作用。靶點(diǎn)
NMDA receptor
體外研究
| Cell Line: | |
| Concentration: | |
| Incubation Time: | |
| Result: |
體內(nèi)研究
Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Lanicemine (3, 10 or 30?mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine.
| Animal Model: | Male Sprague-Dawley rats |
| Dosage: | 3, 10 or 30?mg/kg |
| Administration: | Intraperitoneal |
| Result: | Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity. |